MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.61
-0.14
-2.43%
Closed 16:01 08/09 EDT
OPEN
5.63
PREV CLOSE
5.75
HIGH
5.94
LOW
5.36
VOLUME
133.10K
TURNOVER
--
52 WEEK HIGH
32.19
52 WEEK LOW
2.000
MARKET CAP
226.38M
P/E (TTM)
-2.8248
1D
5D
1M
3M
1Y
5Y
BRIEF-Olema Oncology Advances Op-1250 Into Phase 2 Monotherapy Expansion In Patients With Er+/Her2- Advanced Breast Cancer
BRIEF-Olema Oncology Advances Op-1250 Into Phase 2 Monotherapy Expansion In Patients With Er+/Her2- Advanced Breast Cancer
Reuters · 12h ago
BRIEF-Olema Pharmaceuticals QTRLY Net Loss Per Share $0.82
BRIEF-Olema Pharmaceuticals QTRLY Net Loss Per Share $0.82
Reuters · 13h ago
Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Olema Pharmaceuticals press release (<span clas...
Seekingalpha · 13h ago
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), i...
GlobeNewswire · 14h ago
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference
SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
GlobeNewswire · 5d ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted the...
GlobeNewswire · 6d ago
Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 07/26 11:32
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug
The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.
Zacks · 07/22 10:49
More
No Data
Learn about the latest financial forecast of OLMA. Analyze the recent business situations of Olema Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OLMA stock price target is 14.50 with a high estimate of 16.00 and a low estimate of 12.00.
High16.00
Average14.50
Low12.00
Current 5.61
EPS
Actual
Estimate
-0.51-0.38-0.26-0.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 94
Institutional Holdings: 37.41M
% Owned: 92.70%
Shares Outstanding: 40.35M
TypeInstitutionsShares
Increased
24
1.81M
New
15
3.29M
Decreased
33
5.33M
Sold Out
21
1.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Non-Executive Chairman/Independent Director
Ian Clark
President/Chief Executive Officer/Director
Sean Bohen
Co-Founder/Non-Executive Director
Peter Kushner
Chief Financial Officer/Chief Operating Officer
Shane Kovacs
Executive Vice President/Secretary
John Moriarty
Chief Technology Officer/Director
Cyrus Harmon
Other
Kinney Horn
Other
David Myles
Other
Naseem Zojwalla
Independent Director
Cynthia Butitta
Independent Director
Sandra Horning
Independent Director
Gorjan Hrustanovic
Independent Director
Yi Larson
Independent Director
Andrew Rappaport
Independent Director
Graham Walmsley
No Data
No Data
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It is designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It is in the Phase I/ IIclinical trial, and in Phase I combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Webull offers kinds of Olema Pharmaceuticals Inc stock information, including NASDAQ:OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.